Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study

Evelyn Martínez; Olatz Garin; Yolanda Pardo; Pablo Fernández; Benjamin Guix; Cristina Gutiérrez; Ana Boladeras; Ferran Ferrer; Tania Hernández; Adriana Ayala; Mikel Egiguren; Gema Fernández; Víctor Muñoz; Víctor Macías; Joan Pera; Àngels Pont; Montserrat Ferrer; Ferran Guedea

doi:10.5114/jcb.2021.103580

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

1/2021
vol. 13

Send email

Copy url:

abstract:

Original paper

Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study

Evelyn Martínez

¹

,

Olatz Garin

^{2, 3, 4}

,

Yolanda Pardo

^{2, 3, 5}

,

Pablo Fernández

⁶

,

Benjamin Guix

⁷

,

Cristina Gutiérrez

¹

,

Ana Boladeras

¹

,

Ferran Ferrer

¹

,

Tania Hernández

¹

,

Adriana Ayala

⁶

,

Mikel Egiguren

⁶

,

Gema Fernández

⁸

,

Víctor Muñoz

⁹

,

Víctor Macías

¹⁰

,

Joan Pera

¹

,

Àngels Pont

^{2, 3}

,

Montserrat Ferrer

^{2, 3, 5}

,

Ferran Guedea

¹

Servicio de Oncología Radioterápica, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain

Unidad de Investigación en Servicios Sanitarios, IMIM-Hospital del Mar, Barcelona, Spain

CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

Pompeu Fabra University (UPF), Barcelona, Spain

Universitat Autónoma de Barcelona, Bellaterra, Spain

Servicio de Oncología Radioterápica, Instituto Oncológico de Guipuzkoa, San Sebastián, Spain

Fundación IMOR, Institut Mèdic Onco-Radioterapia, Barcelona, Spain

Servicio de Oncología Radioterápica, Hospital Universitario Central de Asturias, Oviedo, Spain

Servicio de Oncología Radioterápica, Hospital do Meixoeiro, Vigo, Spain

10.

Servicio de Oncología Radioterápica, Hospital Universitari i Politècnic La Fe, Valencia, Spain, and Hospital Universitari General de Catalunya Quiron Salut, Sant Cugat del Vallés, Barcelona, Spain

J Contemp Brachytherapy 2021; 13, 1: 1–11

DOI: https://doi.org/10.5114/jcb.2021.103580

Online publish date: 2021/02/18

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Martínez E, Garin O, Pardo Y, et al. Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy. 2021;13(1):1-11. doi:10.5114/jcb.2021.103580.

APA

Martínez, E., Garin, O., Pardo, Y., Fernández, P., Guix, B.,  & Gutiérrez, C. et al. (2021). Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy, 13(1), 1-11. https://doi.org/10.5114/jcb.2021.103580

Chicago

Martínez, Evelyn, Olatz Garin, Yolanda Pardo, Pablo Fernández, Benjamin Guix, Cristina Gutiérrez,  and Ana Boladeras et al. 2021. "Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study". Journal of Contemporary Brachytherapy 13 (1): 1-11. doi:10.5114/jcb.2021.103580.

Harvard

Martínez, E., Garin, O., Pardo, Y., Fernández, P., Guix, B., Gutiérrez, C., Boladeras, A., Ferrer, F., Hernández, T., Ayala, A., Egiguren, M., Fernández, G., Muñoz, V., Macías, V., Pera, J., Pont, À., Ferrer, M.,  and Guedea, F. (2021). Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy, 13(1), pp.1-11. https://doi.org/10.5114/jcb.2021.103580

MLA

Martínez, Evelyn et al. "Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study." Journal of Contemporary Brachytherapy, vol. 13, no. 1, 2021, pp. 1-11. doi:10.5114/jcb.2021.103580.

Vancouver

Martínez E, Garin O, Pardo Y, Fernández P, Guix B, Gutiérrez C et al. Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy. 2021;13(1):1-11. doi:10.5114/jcb.2021.103580.

Introduction
Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa.

Material and methods
Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires.

Results
A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0.028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups.

Conclusions
After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.

keywords:

Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study

quality of life, prostate cancer, external beam radiotherapy, high-dose-rate brachytherapy